Innate Pharma S.A. ADR IPHA

$1.33 -0.07 (-5.00%)

Valuation

Market cap
156,407,000
Revenue TTM
$10,190,000
Net income TTM
$-55,640,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-546.03%
Debt to equity
-0.50

Trading

Volume
69,300
Avg volume
37,358
Day's range
$1.32 – $1.35
Shares out
111,719,000
Stochastic %K
4%
Beta
0.78
Analysts
Strong Buy
Price target
$6.67

Price

Company profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting...

Show more

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Industry
Biotechnology
Sector
Healthcare
Phone
33 4 30 30 30 30
Website
https://www.innate-pharma.com
Address
117, Avenue de Luminy, BP 30191, Marseille, France

Latest news

Stocktwits

dgbio Oct 28, 5:58 PM
$IPHA Monalizumab trial results are delayed until H1 2027. This is a mild positive. The trial is fully enrolled and event-driven. Fewer events than expected may mean some good efficacy in at least one arm of the trial (there's another arm, with anti-CD73 Ab).
0 replies
G101SPM Oct 27, 10:03 AM
$IPHA $1.46 Holding long position a loss RETAIN LONG POSITION BRIEF: IPHA said AstraZeneca (AZN) updated the expected high-level data readout for the PACIFIC-9 Phase 3 trial to 1H27 from 2H26 previously. The company said the timing change reflects the event-driven nature of the study; enrollment is complete. PACIFIC-9 is evaluating durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC after platinum-based chemoradiation. Monalizumab is an anti-NKG2A antibody developed by Innate in collaboration with AstraZeneca.
0 replies
STACKD0E Oct 27, 9:45 AM
👁 $UUUU $CLLS $IPHA $PHAR
0 replies
focafoca99 Oct 27, 7:18 AM
$IPHA updated the PACIFIC-9 Phase 3 readout timeline to H1 2027, pushing it back from H2 2026.
0 replies
neo55 Oct 20, 6:50 PM
$IPHA in the middle of Nov we should be receive big news do your research on this one can be very big
1 replies
focafoca99 Oct 20, 9:52 AM
$IPHA scheduled its third-quarter 2026 business and financial update call for Nov 5.
0 replies
MikeBob15 Oct 2, 2:04 PM
$IPHA Does this thing have a pulse? 30 min in and 5k shares on a 1.50 stock. NP. Much LOVE for FRANCE.
0 replies
DrKavi Sep 30, 12:52 PM
$IPHA time to wake up
0 replies